SEC Form 4														
FORM 4	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB APPROVAL						
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Filed pursuar	I pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person [*] <u>Murcko Mark</u>			2. Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [RLAY]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	(First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023						e title Other (spe below)				
C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR			nendment, Date of	Month/Day/Ye	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person									
(Street) CAMBRIDGE MA 02139											orm filed by More than One Reporting erson			
(City) (State) ((Zip)	□ Ch	 Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intend satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 								ded to			
Tabl	e I - Non-De	erivative S	ecurities Acqu	uired,	Disp	osed of, o	r Bene	eficially	Owned					
Date		ransaction e onth/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Follow Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			(1130.4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Deemed Execution Date,	4. 5. Number Transaction of			6. Date Exerc Expiration Da	ate	7. Title and Amount of		Derivative	9. Number of derivative	10. Ownership		
Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code (Ir 8)	nstr.	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$11.14	05/31/2023		A		66,055		(1)	05/30/2033	Common Stock	66,055	\$0.00	66,055	D	

Explanation of Responses:

1. This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Remarks:

<u>/s/ Brian Adams, as Attorney-</u> <u>in-Fact</u> <u>06/01/2023</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.